Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Trial Profile

A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Birtamimab (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Adverse reactions
  • Sponsors Onclave Therapeutics; Prothena
  • Most Recent Events

    • 23 Apr 2018 Status changed from recruiting to discontinued, according to a Prothena media release.
    • 23 Apr 2018 According to a Prothena media release, based on the results of PRONTO study, the independent data monitoring committee reviewed a futility analysis of the VITAL study and recommended a discontinuation of the VITAL study as well as the open label extension studies for futility.
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top